Gossamer Bio Faces Major Setback as Phase 3 PROSERA Trial Results Fail to Meet Expectations Gossamer Bio, Inc. suffers a significant drop in stock value following disappointing Phase 3 trials, raising concerns among investors and stakeholders.

Gossamer Bio Faces Major Setback as Phase 3 PROSERA Trial Results Fail to Meet Expectations #USA #New_York #Gossamer_Bio #seralutinib #PROSERA_Trial